价格

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

100-101-TOUR FRANKLIN, Puteaux, Île-de-France, 法国

概览

试验阶段分布

阶段

试验数

占比

1 期

100.0%

试验状态分布

进行中（未招募）

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

VELTASSA 1 G POLVO PARA SUSPENSION ORAL

KAPRUVIA 50 MICROGRAMOS/ML SOLUCION INYECTABLE

CIMA_AEMPS

2022-07-21

TAVNEOS 10 MG CAPSULAS DURAS

RAYALDEE 30 MICROGRAMOS CAPSULAS BLANDAS DE LIBERACION PROLONGADA

CIMA_AEMPS

2020-12-30

VELTASSA 16,8 G POLVO PARA SUSPENSION ORAL

CIMA_AEMPS

2018-02-20

VELTASSA 8,4 G POLVO PARA SUSPENSION ORAL

CIMA_AEMPS

2018-02-19

资讯

暂无资讯文章

返回机构列表

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（4）

A Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate(Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia

A Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate(Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia

A Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate(Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia

A Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate(Phoslyra®) in Paediatric and Adolescent CKD Patients with Hyperphosphataemia

药物批准

按机构分类的批准

近期批准

资讯